ArticleClinical and translational gastroenterology2025
Adherence to Multitarget Stool DNA Testing in Individuals Aged 45-49 Years With Average Risk for Colorectal Cancer.
Article in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Adherence to Obstetrician-/Gynecologist-Ordered Multi-target Stool DNA Test Screening and Follow-Up Colonoscopy: A National Multi-payer Study of US Women.Advances in therapy · 2026Article
- Real-World Completion of Multitarget Stool DNA Testing Among Texas Medicare Beneficiaries: Associations With Payer Type, Digital Outreach, and Social Vulnerability.Journal of health economics and outcomes research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecommendations for colorectal cancer (CRC) screening have been updated to include individuals aged 45-49 years, addressing recent increases in CRC rates among young adults. The multitarget stool DNA (mt-sDNA) test is approved for average-risk individuals aged 45-49 years and is a noninvasive, at-home, stool-based option. This real-world study quantified mt-sDNA screening adherence rates for individuals aged 45-49 years.
methodsThis was a retrospective analysis of individuals aged 45-49 years with average risk for CRC and no history of mt-sDNA testing. Individuals received an mt-sDNA test kit based on a point-of-care order. Adherence was defined as the return of a kit resulting in a valid test result within 1 year of prescription.
resultsA total of 1,126,523 individuals were included. Most (58.6%) were female, and 62.2% received digital communications about the test through text message only. Overall, 68.9% returned their mt-sDNA kit within 1 year. Across provider types, adherence was highest for individuals who were prescribed the test by a gastroenterologist (75.5%); among payor types, adherence was highest for those enrolled in commercial insurance (70.9%). Adherence was lowest for individuals who did not receive any digital communications (54.9%) vs those who did. In a logistic regression analysis, digital communication and payor type were the strongest predictors of adherence. DISCUSSION: In this large real-world study, 68.9% of individuals aged 45-49 years returned an mt-sDNA CRC screening test within 1 year. Increasing digital communication may improve mt-sDNA screening adherence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.